asthma
caus
enorm
suffer
cost
children
us
around
world
comorbid
gastroesophag
reflux
diseas
gerd
make
asthma
manag
difficult
due
increas
symptom
proton
pump
inhibitor
ppi
drug
effect
improv
gerd
symptom
howev
demonstr
modest
variabl
effect
asthma
control
set
comorbid
gerd
importantli
ppi
metabol
efficaci
depend
genotyp
genotyp
tailor
treatment
symptomat
acid
reflux
children
uncontrol
asthma
genara
studi
random
doubleblind
placebocontrol
trial
determin
genotypetailor
ppi
dose
improv
asthma
symptom
among
children
inadequ
control
asthma
gerd
symptom
studi
innov
design
assess
efficaci
genotypetailor
ppi
dose
perform
pharmacokinet
model
oral
ppi
lansoprazol
children
age
year
old
cliniciandiagnos
asthma
mild
gerd
symptom
submit
saliva
sampl
genotyp
particip
undergo
twostep
random
genotypetailor
versu
convent
dose
openlabel
oral
lansoprazol
pharmacokinet
model
genotypetailor
lansoprazol
daili
versu
placebo
week
determin
effect
genotypetailor
ppi
dose
asthma
control
measur
asthma
control
spirometri
nasal
wash
acut
ill
collect
interv
throughout
studi
genara
better
defin
effect
genotyp
dose
respons
lansoprazol
children
adolesc
assess
novel
dose
regimen
improv
gerd
asthma
control
asthma
remain
difficult
control
mani
patient
particularli
children
comorbid
condit
obes
gastroesophag
reflux
diseas
year
year
asthma
lead
caus
pediatr
urgent
care
visit
ed
visit
hospit
icu
admiss
asthma
also
caus
chronic
symptom
alway
lead
healthcar
util
caus
diminish
qualiti
life
reduc
sleep
qualiti
miss
school
day
reduc
extracurricular
particip
person
approach
tailor
atrisk
high
morbid
group
hold
promis
improv
asthma
care
decad
data
result
anim
model
epidemiolog
studi
human
esophag
acid
instil
studi
ph
probe
asthma
symptom
correspond
studi
surgic
fundopl
followup
studi
suggest
gerd
contribut
poor
asthma
control
past
trial
studi
effect
proton
pump
inhibitor
asthma
symptom
children
shown
inconsist
result
tabl
current
literatur
suggest
antigerd
medic
consist
improv
asthma
outcom
divers
cohort
patient
gerd
symptom
partial
inconsist
respons
drug
known
variabl
clearanc
within
popul
case
ppi
consist
pharmacogenet
effect
ppi
inhibit
gastric
hk
atpas
final
effector
acid
secret
pathway
gastric
pariet
cell
firstlin
therapi
gerd
ppi
metabol
primarili
hepat
enzym
gene
highli
polymorph
metabol
pharmacokinet
ppi
variabl
depend
diplotyp
individu
classifi
poor
metabol
pm
normal
metabol
nm
intermedi
metabol
im
extens
metabol
em
ultrarapid
metabol
um
tabl
littl
pk
research
among
metabol
phenotyp
conduct
children
current
children
larg
extrapol
adult
find
major
health
safeti
concern
therefor
genara
studi
design
random
doubleblind
placebocontrol
week
intervent
studi
determin
genotypetailor
ppi
dose
improv
asthma
symptom
among
children
inadequ
control
asthma
recent
evid
mild
gerd
symptom
genara
measur
chang
junip
asthma
control
questionnair
acq
primari
outcom
evalu
asthma
gerd
control
lansoprazol
safeti
pharmacokinet
genara
studi
multicent
control
parallel
group
intervent
trial
involv
children
asthma
gerd
symptom
random
either
genotypetailor
lansoprazol
placebo
tabl
studi
review
thrasher
research
fund
food
drug
administr
ind
institut
review
board
particip
site
genara
select
criteria
establish
studi
children
inadequ
control
asthma
mild
gerdrel
symptom
criteria
enrollmentinclus
age
year
old
document
cliniciandiagnos
asthma
evid
recent
uncontrol
asthma
must
meet
least
one
follow
acq
use
shortact
betaagonist
asthma
symptom
twiceweek
averag
past
month
nocturn
awaken
asthma
symptom
per
week
averag
last
month
two
emerg
depart
visit
unschedul
provid
visit
prednison
cours
hospit
asthma
past
month
current
stabl
dose
daili
inhal
corticosteroid
medic
asthma
control
equival
fluticason
greater
least
week
time
enrol
particip
must
nation
asthma
educ
prevent
program
naepp
control
step
current
mild
gerd
symptom
report
visit
defin
score
pediatr
gerd
symptom
assess
score
gsa
rang
higher
score
repres
wors
gerd
symptom
criteria
enrollmentexclus
particip
could
take
follow
daili
substrat
induc
inhibitor
medic
past
current
histori
sever
gerd
relat
disord
eros
esophag
peptic
ulcer
diseas
eosinophil
esophag
opinion
pediatr
gastroenterolog
safeti
specialiststudi
physician
requir
treatment
acidblock
agent
sinc
particip
may
receiv
placebo
daili
use
ppi
consecut
week
past
month
previou
intub
asthma
admiss
intens
care
unit
h
asthma
past
year
previou
surgeri
involv
esophagu
stomach
antireflux
surgeri
peptic
ulcer
surgeri
tracheesophag
fistula
repair
forc
expiratori
volum
predict
enrol
major
chronic
ill
would
interfer
particip
intervent
complet
studi
procedur
histori
phenylketonuria
medic
use
treatment
gerd
symptom
overthecount
antacid
daysweek
averag
past
month
theophyllin
prepar
azol
anticoagul
insulin
type
diabet
digitali
oral
iron
supplement
administ
iron
defici
within
month
investig
drug
within
past
month
drug
allergi
previou
allerg
reaction
lansoprazol
proton
pump
inhibitor
medic
advers
reaction
tabl
pediatr
asthma
studi
involv
proton
pump
inhibitor
ppi
ob
observ
studi
rct
random
control
trial
ppi
proton
pump
inhibitor
gerd
gastroesophag
reflux
diseas
aspartam
inabl
complet
baselin
measur
satisfactori
manner
accord
judgment
research
coordin
site
pi
complet
daili
diari
asthma
symptom
saba
use
ic
medic
adher
runin
period
plan
famili
move
studi
locat
within
next
month
particip
elig
random
administ
open
label
dose
either
convent
genotypetailor
lansoprazol
visit
pharmacokinet
analysi
particip
subsequ
random
either
genotypetailor
lansoprazol
genotypetailor
dose
tabl
placebo
placebo
includ
equal
volum
liquid
suspens
sweeten
similar
tast
consist
activ
commerciallyavail
lansoprazol
placebo
liquid
manufactur
suppli
cuti
pharma
inc
wilmington
elig
particip
monitor
day
screen
prior
random
runin
period
assess
asthma
gerd
sever
diari
card
adher
particip
undergo
twostep
random
process
first
particip
given
singl
oral
dose
lansoprazol
randomli
assign
either
conventionallydos
lansoprazol
dose
accord
tabl
genotypetailor
dose
second
random
intervent
period
either
genotypetailor
ppi
dose
match
placebo
random
intervent
ratio
stratifi
site
neither
particip
research
staff
inform
treatment
group
assign
maintain
doublemask
lansoprazol
commerci
avail
gener
welltoler
side
effect
assess
clinic
visit
telephon
visit
trial
fig
patient
mild
gerd
persist
degre
asthma
symptom
exist
reason
equipois
regard
role
longterm
ppi
use
thu
use
placebocontrol
safeti
monitor
place
justifi
particip
regardless
random
receiv
educ
diet
lifestyl
modif
reduc
gerd
outlin
patient
handout
gerd
children
adolesc
publish
jointli
two
expert
organ
subject
continu
previous
prescrib
asthma
control
regimen
studi
particip
seek
care
prespecifi
asthma
physician
studi
pi
also
avail
asthma
problem
clinic
care
question
prespecifi
threshold
criteria
start
oral
steroid
asthma
refer
lossoffunct
inact
allel
nrefer
lossoffunct
allel
pkpharmacokinet
test
gsa
gerd
symptom
assess
score
exacerb
also
place
consist
past
nihfund
pediatr
asthma
trial
train
research
staff
determin
elig
use
baselin
medic
histori
anthropometr
pulmonari
functionlung
respons
test
asthma
symptom
questionnair
pregnanc
test
femal
visit
guardian
sign
inform
consent
document
particip
start
monitor
runin
period
particip
adher
diari
card
meet
elig
random
visit
complet
daili
diari
asthma
symptom
saba
use
ic
medic
adher
runin
period
prompt
extens
runin
addit
week
discret
investig
time
detail
data
collect
tabl
screen
visit
includ
inform
consent
instruct
regard
studi
format
test
per
tabl
saliva
collect
genotyp
perform
identifi
metabol
phenotyp
particip
visit
also
signifi
start
runin
period
visit
staff
review
particip
asthma
action
plan
particip
given
daili
diari
card
document
studi
drug
adher
asthma
symptom
asthma
medic
use
asthmarel
healthcar
contact
random
visit
particip
return
diari
card
nasal
blow
train
collect
undergo
elig
random
given
open
label
dose
lansoprazol
pharmacokinet
analysi
week
intervent
particip
return
daili
diari
card
termin
visit
test
perform
per
tabl
receiv
exit
letter
detail
genotyp
counsel
inform
regard
asthma
gerd
chang
junip
asthma
control
questionnair
acq
primari
outcom
measur
use
mani
welldesign
multicent
asthma
trial
children
acq
rang
higher
valu
indic
wors
asthma
control
chang
reflect
clinic
meaning
differ
asthma
control
consid
broad
set
control
indic
includ
use
bronchodil
cough
nocturn
symptom
level
activ
pulmonari
function
visit
also
perform
asthma
symptom
util
index
asui
comput
rate
preval
asthma
symptom
exacerb
treatment
group
use
approv
spirometr
system
appropri
calibr
procedur
conduct
per
american
thorac
societi
standard
outcom
includ
forc
vital
capac
fvc
forc
expiratori
volum
raw
data
percent
predict
valu
record
base
accept
norm
data
chang
pediatr
gerd
symptom
assess
questionnair
gsa
measur
tool
valid
children
assess
gastroesophag
reflux
diseas
relat
symptom
chest
abdomin
pain
pain
choke
eat
swallow
dysfunct
regurgit
nausea
gsa
rang
score
reflect
signific
gerd
symptom
valu
use
maximum
cutoff
mild
symptom
sd
mean
gsa
children
without
baselin
gerd
concentr
lansoprazol
metabolit
quantifi
use
liquid
chromatographymass
spectroscopi
describ
method
sensit
high
perform
liquid
chromatographi
metabolit
requir
less
plasma
blood
character
impact
genet
polymorph
doseconcentr
respons
relationship
lansoprazol
develop
physiologicallybas
pharmacokinet
pbpk
model
integr
inform
drug
physiochem
properti
eg
molecular
weight
logp
pka
phdeepend
solubl
human
anatomi
physiolog
pbpk
model
develop
base
avail
literatur
data
use
prospect
sensit
analys
show
peak
plasma
concentr
approxim
h
shift
later
higher
gastric
ph
base
preliminari
analysi
blood
drawn
h
post
openlabel
genotypetailor
dose
use
popul
pkpd
techniqu
comput
area
curv
particip
perform
efficaci
analysi
develop
pediatr
popul
pkpd
model
establish
relationship
dose
convent
plasma
concentr
lansoprazol
metabol
phenotyp
plasma
concentr
also
compar
chang
gerd
symptom
model
develop
qualifi
three
step
outlin
exploratori
analysi
pk
gerd
symptom
score
data
exploratori
analysi
perform
determin
relationship
lansoprazol
pk
gerd
score
identifi
potenti
outlier
explor
impact
genet
polymorph
chang
gerd
symptom
nonlinear
mix
effect
model
approach
perform
nonmem
higher
determin
structur
model
adequ
describ
pk
lansoprazol
allow
estim
respect
model
paramet
appropri
structur
model
select
varianc
structur
model
inform
use
pool
data
intens
spars
sampl
period
studi
signific
covari
particularli
genet
polymorph
assess
use
autom
stepwis
covari
model
build
method
method
involv
forward
select
backward
elimin
covari
one
model
relev
parametercovari
relationship
prepar
test
univari
manner
statist
criterion
pvalu
object
function
valu
ofv
degre
freedom
assum
chisquar
distribut
forward
select
pvalu
degre
freedom
assum
chisquar
distribut
backward
elimin
use
indic
relat
interest
inclus
drop
ofv
use
rank
covari
import
parametercovari
relationship
model
largest
drop
ofv
use
includ
covari
largest
parametercovari
relationship
model
goodnessoffit
appropri
final
model
scm
assess
diagnost
plot
physiolog
meaning
obtain
paramet
estim
visual
predict
check
nonparametr
bootstrap
c
develop
popul
pkpd
model
variou
empir
popul
pkpd
model
report
ppi
adult
none
children
popul
pkpd
model
efficaci
lansoprazol
children
establish
link
poppk
model
develop
b
appropri
pd
model
order
identifi
appropri
pd
model
emax
sigmoid
emax
indirect
respons
explor
best
model
select
base
standard
goodnessoffit
plot
reduct
ofv
visual
predict
check
addit
agedepend
chang
synthesi
rate
proton
pump
well
circadian
rhythm
relat
gastric
acid
secret
food
effect
consid
model
develop
nasal
blow
collect
techniqu
previous
valid
within
asthmanet
consortium
parent
train
visit
identifi
earli
respiratori
infect
symptom
collect
store
nasal
wash
sampl
multiplex
pcr
analysi
perform
relev
respiratori
viral
bacteri
pathogen
see
tabl
use
taqman
assay
valid
cdc
inflammatori
mechan
assess
type
interferon
leptin
level
nasal
wash
sampl
genara
studi
initi
duke
children
hospit
expand
nemour
children
health
system
jacksonvil
florida
data
safeti
monitor
board
creat
monitor
safeti
data
integr
met
yearli
investig
new
drug
applic
submit
section
feder
food
drug
cosmet
act
genotypetailor
lansoprazol
intervent
grant
studi
data
collect
manag
use
research
electron
data
captur
redcap
electron
data
captur
system
tool
host
collabor
within
duke
clinic
research
institut
redcap
chosen
secur
webbas
applic
design
support
data
captur
research
studi
provid
intuit
interfac
valid
data
entri
audit
trail
track
data
manipul
export
procedur
autom
export
procedur
seamless
data
download
common
statist
packag
procedur
import
data
extern
sourc
determin
particip
need
random
accord
alloc
ratio
goal
receiv
genotypetailor
lansoprazol
receiv
placebo
power
estim
effect
lansoprazol
acq
chang
baselin
perform
use
twosid
ttest
error
rate
base
preliminari
data
patient
popul
anticip
mean
acq
entri
standard
deviat
aim
detect
acq
chang
assum
attrit
final
goal
particip
complet
intervent
achiev
power
also
power
detect
differ
group
respiratori
infect
differ
detect
differ
due
low
assum
background
rate
exacerbationyear
power
detect
differ
asthma
exacerb
assum
intentiontotreat
approach
trial
end
use
two
sampl
ttest
ancova
determin
whether
chang
acq
random
termin
visit
differ
treatment
group
secondari
outcom
continu
numer
variabl
analyz
similarli
count
data
asthma
exacerb
episod
poor
respiratori
tract
infect
employ
poisson
regress
analysi
statist
packag
sa
sa
institut
inc
cari
nc
use
test
twotail
level
signific
genara
studi
aim
determin
genotypetailor
dose
lansoprazol
children
inadequ
control
asthma
lead
improv
asthma
control
consid
frequent
prescript
ppi
patient
asthma
understand
relationship
genotypetailor
dose
asthma
control
crucial
determin
efficaci
safeti
prior
studi
adult
children
demonstr
efficaci
ppi
treat
gerd
relat
condit
close
link
plasma
concentr
numer
studi
adult
shown
variant
markedli
influenc
pk
pd
ppi
patient
need
acidsuppress
em
um
higher
treatment
failur
rate
compar
nm
given
convent
dose
h
pylori
cure
rate
significantli
higher
among
pm
compar
em
higher
dose
ppi
requir
erad
h
pylori
em
recent
studi
children
also
demonstr
import
variant
clearanc
pantoprazol
estim
pediatr
patient
birth
year
lower
pm
compar
em
group
compar
drug
level
follow
singl
dose
convent
dose
lansoprazol
genotypemetabol
phenotyp
children
gerd
found
direct
relationship
diplotyp
lansoprazol
concentr
also
recent
found
em
children
convent
ppi
dose
undergo
esophag
ph
probe
test
inadequ
acid
blockad
compar
nm
pm
addit
group
recent
assess
children
fail
ppi
therapi
subsequ
underw
surgic
gastric
fundopl
also
avail
endoscop
tissu
sampl
dna
genotyp
children
fail
ppi
requir
fundopl
significantli
like
em
phenotyp
compar
control
significantli
fewer
children
fail
ppi
need
fundopl
pm
phenotyp
compar
control
collect
data
support
hypothesi
em
um
children
underdos
convent
ppi
dose
benefit
higher
genotypetailor
dose
ppi
achiev
optim
antisecretori
respons
addit
treatment
ppi
consist
associ
number
advers
sideeffect
includ
c
dificil
coliti
respiratori
infect
group
show
ppi
use
convent
dose
month
asthmat
children
without
signific
gerd
baselin
associ
significantli
greater
sinus
strep
throat
uri
subsequ
genet
substudi
show
particip
im
pm
significantli
higher
lansoprazol
level
compar
nm
significantli
like
suffer
respiratori
advers
event
relat
uri
strepsor
throat
pm
particip
develop
wors
asthma
control
trigger
uri
compar
nm
month
convent
ppi
dose
convent
dose
ppi
im
pm
patient
like
improv
gerd
symptom
cost
greater
risk
uri
sinc
uri
common
trigger
loss
asthma
control
children
convent
dose
may
ultim
help
asthma
control
due
greater
uri
instead
propos
im
pm
patient
could
given
genotypetailor
dose
provid
normal
serum
concentr
improv
gerd
symptom
risk
excess
uri
collect
nasal
wash
sampl
particip
uri
microbiolog
confirm
uri
result
broad
applic
patient
possess
signific
variant
sizeabl
segment
popul
fact
popul
nm
phenotyp
impm
em
um
phenotyp
make
popul
respect
loss
function
allel
n
loss
function
allel
eg
snp
reduc
drug
clearanc
increas
area
curv
auc
gain
function
allel
increas
drug
clearanc
prior
pk
data
children
support
use
five
distinct
metabol
phenotyp
warrant
distinct
dose
adjust
convent
twotier
dose
develop
evidencedbas
dose
algorithm
tailor
extens
em
ultrarapid
um
intermedi
im
poor
metabol
pm
base
pediatr
pk
principl
analyz
limit
extant
pediatr
data
estim
also
agreement
propos
furuta
yet
untest
children
innov
clinic
trial
design
import
combat
lack
pediatr
studi
challeng
therein
studi
design
twostep
random
studi
pharmacokinet
efficaci
particip
random
open
label
convent
genotypetailor
lansoprazol
pk
analysi
genotypetailor
lansoprazol
placebo
intervent
part
random
stratifi
base
result
part
random
felt
impact
chang
acq
month
would
minim
though
theoret
possibl
character
effect
ppi
asthma
also
made
specif
choic
safe
specif
measur
efficaci
lansoprazol
approv
fda
age
month
indic
gerd
duoden
ulcer
h
pylori
erad
benign
gastric
ulcer
nsaidassoci
gastric
ulcer
eosinophil
esophag
patholog
hypersecretori
condit
use
patient
phase
ii
iii
clinic
trial
involv
vari
dose
durat
found
welltoler
shortterm
longterm
trial
rare
case
patient
report
diarrhea
constip
abdomin
pain
nausea
use
lansoprazol
current
fda
label
lansoprazol
state
ppi
therapi
may
associ
increas
risk
c
difficil
associ
diarrhea
long
term
multipl
daili
dose
ppi
therapi
may
associ
increas
risk
osteoporosisrel
fractur
hip
wrist
spine
hypomagnesemia
rare
includ
mild
gerd
chose
exclud
children
enrol
gsa
previou
studi
patient
popul
shown
children
without
diagnos
gerd
gsa
score
rang
mean
sd
threshold
chosen
sd
mean
gsa
group
children
without
report
gerd
baselin
select
acq
primari
outcom
sensit
measur
asthma
control
valid
children
adult
spanish
english
simplic
summari
develop
innov
clinic
trial
assess
efficaci
genotypetailor
ppi
dose
treatment
asthma
studi
benefit
children
gerd
asthma
futur
better
understand
dose
respons
character
safeti
profil
lansoprazol
trial
design
may
applic
clinic
trial
discoveri
pharmacogenom
therapi
need
pediatr
pharmacokinet
studi
continu
grow
result
genara
studi
show
genotypetailor
dose
efficaci
safer
children
asthma
futur
treatment
children
asthma
gerd
greatli
improv
studi
fund
thrasher
research
fund
id
author
indic
financi
relationship
relev
articl
disclos
